Ninerafaxstat (trihydrochloride)

Ninerafaxstat trihydrochloride (IMB-1018972 trihydrochloride) is the trihydrochloride salt form of Ninerafaxstat (HY-139577) . Ninerafaxstat trihydrochloride is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat trihydrochloride competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat trihydrochloride can be used for research on cardiovascular diseases[1][2].

Product Specifications

CAS Number

[2311824-72-1]

Product Name Alternative

MB-1018972 (trihydrochloride) ; IMB-101 (trihydrochloride)

UNSPSC

12352005

Target

Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ninerafaxstat-trihydrochloride.html

Purity

99.65

Solubility

DMSO : 41.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC=CN=C1)OCCN2CCN(CC3=CC=C(OC)C(OC)=C3OC)CC2.[H]Cl.[H]Cl.[H]Cl

Molecular Formula

C22H32Cl3N3O5

Molecular Weight

524.87

References & Citations

[1]Moritz Hundertmark MD, et al. Kiosk 11R-TC-08 - Ninerafaxstat Modulates Cardiac Energy Metabolism in Cardio-metabolic Syndromes: A Mechanistic, Hyperpolarized MR Trial. Journal of Cardiovascular Magnetic Resonance. 2024; 26: 100325.|[2]Paul Chamberlin, et al. IMB-1018792, A NOVEL FIRST-IN CLASS PARTIAL FATTY ACID OXIDATION INHIBITOR IMPROVES CARDIAC REMODELING AND FUNCTION POST-MYOCARDIAL INFARCTION. J Am Coll Cardiol. 2021 May 11;77 (18) :539.